There is disagreement on the optimal timing of HAART initiation based on absolute CD4(+) T-cell count (CD4(+) count). We investigated if naive patients with CD4(+) T-cell percentage (%CD4(+)) <29% or CD4(+)/CD8(+) ratio <1 display signs of immune deterioration notwithstanding CD4(+) count >= 500 cells/mu l. We found that these patients show B-cell aberrations and an impaired control of Torque Teno Virus replication. By contrast, patients with CD4(+)>= 500/mu l, %CD4(+)>= 29% and CD4(+)/CD8(+)>= 1 displayed features of healthy subjects. Results obtained suggest that a combination of these parameters could be an adequate surrogate marker of immunological competence. This will be helpful in deciding when to start HAART.

For timing of HAART is less more? CD4(+)/CD8(+) ratio and CD4(+) percentage as surrogate markers for more complex immunological features

Torti C;
2014-01-01

Abstract

There is disagreement on the optimal timing of HAART initiation based on absolute CD4(+) T-cell count (CD4(+) count). We investigated if naive patients with CD4(+) T-cell percentage (%CD4(+)) <29% or CD4(+)/CD8(+) ratio <1 display signs of immune deterioration notwithstanding CD4(+) count >= 500 cells/mu l. We found that these patients show B-cell aberrations and an impaired control of Torque Teno Virus replication. By contrast, patients with CD4(+)>= 500/mu l, %CD4(+)>= 29% and CD4(+)/CD8(+)>= 1 displayed features of healthy subjects. Results obtained suggest that a combination of these parameters could be an adequate surrogate marker of immunological competence. This will be helpful in deciding when to start HAART.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/6362
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact